Ultralong-segment Barrett's Esophagus: Towards a Capsule-sponge Surveillance Strategy
ConditionBarrett Esophagus
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorErasmus Medical Center
About this trial
The purpose of this study is to evaluate the Endosign capsule sponge test as a novel surveillance method in patients with an ultralong-segment Barrett's esophagus.
Eligibility criteria
Qualifiers
Any participant 18 years and above, with ultralong-segment Barrett's esophagus and clinically fit for an endoscopy
Ability to provide informed consent
Disqualifiers
Individuals with a diagnosis of an oro-pharynx, esophageal or gastro-esophageal tumor (T2 staging and above), or symptoms of dysphagia
Esophageal varices or stricture requiring dilatation of the esophagus
Individuals who have had a cerebrovascular event < 6 months prior where their swallowing has been affected
Patients who have had previous treatments such as Photodynamic therapy (PDT), Radiofrequency ablation (RFA) or Argon Plasma Coagulation (APC) for dysplastic Barrett's esophagus
Trial design
Treatments tested in this trial
- EndoSign
Treatment groups
137 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov